Premium
High‐dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non‐Hodgkin's lymphoma
Author(s) -
Tura Sante,
Mazza Patrizio,
Gherlinzoni Filippo,
Ricci Paolo,
Visani Giuseppe,
Bandini Giuseppe,
Zaccaria Alfonso,
Rosti Gianantonio,
Lauria Franscesco,
Baccarani Michele,
Zinzani Pier Luigi,
Poletti Giovanni,
Motta Maria Rosa,
Rizzi Simona,
Verlicchi Franco,
Finelli Carlo
Publication year - 1986
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1986.tb02325.x
Subject(s) - medicine , lymphoma , surgery , bone marrow , transplantation , non hodgkin's lymphoma , stage (stratigraphy) , oncology , paleontology , biology
13 previously untreated patients with poor prognosis non‐Hodgkin's lymphoma (NHL) underwent high‐dose therapy followed by autologous bone marrow transplantation (ABMT). All patients experienced a great cytoreductive effect and 9 of them reached a complete remission (mean duration 32 months). The best results were observed in patients with more limited disease and in those without symptoms. 7 patients still remain in complete unmantained remission 15–46 months from the transplant. The probability of survival is 74% at 46 months. No therapy‐related deaths were recorded. In differentiating our preliminary approach, we propose high dose therapy followed by ABMT as induction phase in patients with stage II and as consolidation after first line therapy in patients with stages III‐IV. Further studies are warranted to determine which type of lymphoma may benefit more and which conditioning regimens may improve the remission rate.